Nanjing Leads Biolabs Added to Hang Seng Composite Index and Stock Connect Southbound List

Nanjing Leads Biolabs Co., Ltd. Class H ( (HK:9887) ) has issued an update.

Nanjing Leads Biolabs Co., Ltd. announced that, effective March 9, 2026, its shares will become a constituent of the Hang Seng Composite Index and will be included in the list of eligible securities for the Stock Connect Southbound Trading Link. This dual inclusion signals strong capital market recognition of the company’s performance and value, and is expected to broaden its mainland investor base, enhance trading liquidity in its Hong Kong-listed shares, and further optimize its shareholder structure.

The move will enable qualified investors in mainland China to directly trade Nanjing Leads Biolabs’ Hong Kong-listed shares via the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect channels. By deepening access to cross-border capital flows, the company stands to strengthen its market visibility and potentially improve its pricing efficiency and long-term market positioning within the regional biotech investment universe.

The most recent analyst rating on (HK:9887) stock is a Buy with a HK$80.27 price target. To see the full list of analyst forecasts on Nanjing Leads Biolabs Co., Ltd. Class H stock, see the HK:9887 Stock Forecast page.

More about Nanjing Leads Biolabs Co., Ltd. Class H

Nanjing Leads Biolabs Co., Ltd. is a PRC-incorporated joint stock company listed in Hong Kong under stock code 9887, operating in the biopharmaceutical sector. The company focuses on developing and commercializing biotechnology-related products, positioning itself to attract both Hong Kong and mainland Chinese investors through its Hong Kong listing.

Average Trading Volume: 481,496

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$10.27B

For detailed information about 9887 stock, go to TipRanks’ Stock Analysis page.